Clinical trials: Movement Abnormalities
Angelman Syndrome
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome
A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Angelman syndrome
- Trial name
- AS-001 (NCT05011851)
- Testing
- NNZ-2591
- Where
- 3 sites in Australia
- Volunteers
- 17 people
- Sponsor
- Neuren Pharmaceuticals Limited
Parkinson Disease
Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone
The purpose of this study is to evaluate the bioavailability and the bioequivalence between two active pharmaceutical ingredient (API) sources of opicapone (OPC) at two different dosage strengths (25 mg and 50 mg) after a single…
- Trial name
- NCT03116295
- Testing
- Opicapone (OPC)
- Where
- Germany
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With "Wearingoff" Phenomenon
The purpose of this study was to investigate the effect on the "wearing-off" phenomenon of 3 different doses of nebicapone (NEB 50 mg, 100 mg and 150 mg), compared with entacapone and placebo when dministered concomitantly with…
- Trial name
- NCT03103399
- Testing
- Comtan®, Nebicapone, Levodopa/DDCI
- Volunteers
- 254 people
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)
This is a Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-arm Phase IIa proof of concept in subjects with PD treated with a stable dose of levodopa who are experiencing Motor Complications of Levodopa Therapy
- Trial name
- ATTUNED (NCT03331848)
- Testing
- PXT002331 - 20mg
- Sponsor
- Prexton Therapeutics
Parkinson's Disease
PK, PD and Safety of Multiple Doses of V1512 Tablets in PD Patients Compared to Standard Levodopa/Carbidopa Oral Tablets
The purpose of the study is to determine if the pharmacokinetic profile of V1512 is similar or better than existing medications for the treatment of Parkinson's Disease
- Trial name
- NCT00491998
- Testing
- V1512, V1512 and Entacapone
- Where
- Italy
- Volunteers
- 27 people
- Sponsor
- Vernalis (R&D) Ltd
Huntington Disease
TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease
This study is designed to determine the effect of 2 gram/day of ethyl-EPA on motor (movement) signs and symptoms of Huntington disease.
- Trial name
- NCT00146211
- Testing
- Ethyl-EPA (Miraxion™)
- Where
- 41 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Amarin Neuroscience Ltd
Parkinson's Disease
A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients
A cross-over study, where ND0611 or placebo will be tested on top of 3 different LD/CD dosage forms. Safety and tolerability, pharmacokinetic profile of levodopa and carbidopa and the potential clinical effect of ND0611 will be…
- Trial name
- NCT01229332
- Testing
- Saline, Carbidopa
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- NeuroDerm Ltd.
Parkinson Disease
A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease
This is a double blind, fixed dose, parallel group study to characterize the dose response of ropinirole PR as adjunctive therapy to L-dopa in patients with late stage Parkinson's disease.
- Trial name
- TANDEM-569 (NCT01494532)
- Testing
- ropinirole/L-dopa
- Where
- 52 sites in United States, Argentina and 5 more
- Volunteers
- 352 people
- Sponsor
- GlaxoSmithKline
Parkinson's Disease
A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease
This study examines the efficacy of three doses of IPX066 as compared to placebo in Parkinson's disease.
- Trial name
- APEX-PD (NCT00880620)
- Testing
- IPX066 95 mg LD, IPX066 145 mg LD, IPX066 195 mg LD
- Where
- 60 sites in United States, Canada and 5 more
- Volunteers
- 381 people
- Sponsor
- Impax Laboratories, LLC
Parkinson's Disease
Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off
The purpose of this study is to test the effects of carbidopa/levodopa/entacapone compared to the effects of immediate-release carbidopa/levodopa on non-motor symptoms of end-of-dose wearing off in persons who have Parkinson's…
- Trial name
- NCT00642356
- Testing
- Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa
- Where
- 21 sites in United States
- Volunteers
- 14 people
- Sponsor
- Novartis
Parkinson Disease (PD), Lewy Body Dementia (LBD)
18F-mFBG Cardiac Uptake With Lewy Body Dementia
This is a Phase 2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of the effect of neurodegenerative diseases on myocardial sympathetic innervation.
- Trial name
- IRP101-231 (NCT07176286)
- Testing
- 18F-MFBG
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Parkinson Disease
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa
This is a phase III, multicenter, randomized, double-blind, parallel group, placebo-controlled study to compare the efficacy of 6-months therapy of ropinirole Prolonged Release (PR) with that of placebo as adjunctive therapy to…
- Trial name
- NCT01154166
- Testing
- ReQuip PR
- Where
- 18 sites in China
- Volunteers
- 347 people
- Sponsor
- GlaxoSmithKline
Parkinson's Disease
Relative Bioavailability Study of HRG2010 in Healthy Subjects
This is a single-center, randomized, open-label, four-period, crossover study. Primary Objective： 1. To evaluate the pharmacokinetic characteristics of healthy subjects after a single oral dose of HRG2010 capsules at dose 1 and…
- Trial name
- NCT06976346
- Testing
- HRG2010 Capsule, Sinemet®, Madopar®
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Parkinson's Disease
Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of oral doses of FB-101 in healthy subjects.
- Trial name
- NCT04165837
- Testing
- FB-101
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- 1ST Biotherapeutics, Inc.
Angelman Syndrome
CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adults With Angelman Syndrome (AS)
The primary purpose of the study is to evaluate efficacy of obudanersen in participants with AS due to uniparental disomy or imprinting defects (UPD/ID) as measured through expressive communication.
- Trial name
- NCT07782827
- Testing
- obudanersen
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Parkinson Disease, Parkinson's Disease
Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients
The purpose of this study is to evaluate the dose-related safety and tolerability of IPS101A, an adeno-associated virus (AAV) gene therapy, in patients with Parkinson's disease who exhibit severe functional impairment…
- Trial name
- NCT07371338
- Testing
- IPS101A
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Innopeutics Corporation
Parkinson Disease
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
A Phase 1, randomized, double-blind, placebo-controlled study of BMS-984923 administered orally twice daily (BID) for 28 days in participants with Parkinson's disease.
- Trial name
- NCT06309147
- Testing
- BMS-9894923
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Allyx Therapeutics
Parkinson's Disease
SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's Disease
The aim of the non-interventional Post Marketing Study is to investigate the use of the non-ergot dopamine agonist piribedil (trade name: CLARIUM) in mono- and combination therapy in patients with Morbus Parkinson.
- Trial name
- PIR-001/K (NCT00725478)
- Testing
- Piribedil
- Volunteers
- 250 people
- Sponsor
- Desitin Arzneimittel GmbH
TOURETTE SYNDROME
A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS)
The purpose of this study is to evaluate safety, tolerability and preliminary efficacy of SD-809 in the treatment of motor and phonic tics of Tourette Syndrome and to evaluate the pharmacokinetic of SD-809 and its metabolites.
- Trial name
- NCT02674321
- Testing
- SD-809
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Auspex Pharmaceuticals, Inc.
Parkinson Disease
A Positron Emission Tomography (PET) Study to Examine the Brain Binding Properties of a Novel Radioactive Compound [11C]-PXT012253 in Healthy Subjects
This study evaluates the usefulness of a PET radioligand to estimate the binding on the mGlu4 receptor in the brain. mGlu4 has been proposed as a therapeutic target in Parkinson's disease.
- Trial name
- NCT03826134
- Testing
- [11C]PXT012253
- Where
- Sweden
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.